These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 32107618

  • 1. Oxalobacter formigenes treatment combined with intensive dialysis lowers plasma oxalate and halts disease progression in a patient with severe infantile oxalosis.
    Pape L, Ahlenstiel-Grunow T, Birtel J, Krohne TU, Hoppe B.
    Pediatr Nephrol; 2020 Jun; 35(6):1121-1124. PubMed ID: 32107618
    [Abstract] [Full Text] [Related]

  • 2. Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study.
    Hoppe B, Pellikka PA, Dehmel B, Banos A, Lindner E, Herberg U.
    Nephrol Dial Transplant; 2021 Jul 23; 36(8):1464-1473. PubMed ID: 32810261
    [Abstract] [Full Text] [Related]

  • 3. Reduction of plasma oxalate levels by oral application of Oxalobacter formigenes in 2 patients with infantile oxalosis.
    Hoppe B, Dittlich K, Fehrenbach H, Plum G, Beck BB.
    Am J Kidney Dis; 2011 Sep 23; 58(3):453-5. PubMed ID: 21705122
    [Abstract] [Full Text] [Related]

  • 4. A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
    Hoppe B, Niaudet P, Salomon R, Harambat J, Hulton SA, Van't Hoff W, Moochhala SH, Deschênes G, Lindner E, Sjögren A, Cochat P.
    Pediatr Nephrol; 2017 May 23; 32(5):781-790. PubMed ID: 27924398
    [Abstract] [Full Text] [Related]

  • 5. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.
    Milliner D, Hoppe B, Groothoff J.
    Urolithiasis; 2018 Aug 23; 46(4):313-323. PubMed ID: 28718073
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Oxalobacter formigenes treatment confers protective effects in a rat model of primary hyperoxaluria by preventing renal calcium oxalate deposition.
    Verhulst A, Dehmel B, Lindner E, Akerman ME, D'Haese PC.
    Urolithiasis; 2022 Apr 23; 50(2):119-130. PubMed ID: 35122487
    [Abstract] [Full Text] [Related]

  • 8. Sel1-like proteins and peptides are the major Oxalobacter formigenes-derived factors stimulating oxalate transport by human intestinal epithelial cells.
    Arvans D, Chang C, Alshaikh A, Tesar C, Babnigg G, Wolfgeher D, Kron S, Antonopoulos D, Bashir M, Cham C, Musch M, Chang E, Joachimiak A, Hassan H.
    Am J Physiol Cell Physiol; 2023 Jul 01; 325(1):C344-C361. PubMed ID: 37125773
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria.
    Hoppe B, Groothoff JW, Hulton SA, Cochat P, Niaudet P, Kemper MJ, Deschênes G, Unwin R, Milliner D.
    Nephrol Dial Transplant; 2011 Nov 01; 26(11):3609-15. PubMed ID: 21460356
    [Abstract] [Full Text] [Related]

  • 10. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1.
    Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H.
    Kidney Int; 2006 Oct 01; 70(7):1305-11. PubMed ID: 16850020
    [Abstract] [Full Text] [Related]

  • 11. Combined liver-kidney transplantation for primary hyperoxaluria type 1 in young children.
    Ellis SR, Hulton SA, McKiernan PJ, de Ville de Goyet J, Kelly DA.
    Nephrol Dial Transplant; 2001 Feb 01; 16(2):348-54. PubMed ID: 11158411
    [Abstract] [Full Text] [Related]

  • 12. Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure.
    Hoppe B, Kemper MJ, Bökenkamp A, Portale AA, Cohn RA, Langman CB.
    Kidney Int; 1999 Jul 01; 56(1):268-74. PubMed ID: 10411702
    [Abstract] [Full Text] [Related]

  • 13. Rapid reversal of hyperoxaluria in a rat model after probiotic administration of Oxalobacter formigenes.
    Sidhu H, Allison MJ, Chow JM, Clark A, Peck AB.
    J Urol; 2001 Oct 01; 166(4):1487-91. PubMed ID: 11547118
    [Abstract] [Full Text] [Related]

  • 14. Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
    Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, Sellier-Leclerc AL, Devresse A, Guebre-Egziabher F, Bakkaloglu SA, Mourani C, Saqan R, Singer R, Willey R, Habtemariam B, Gansner JM, Bhan I, McGregor T, Magen D.
    Am J Kidney Dis; 2023 Feb 01; 81(2):145-155.e1. PubMed ID: 35843439
    [Abstract] [Full Text] [Related]

  • 15. Forty Years of Oxalobacter formigenes, a Gutsy Oxalate-Degrading Specialist.
    Daniel SL, Moradi L, Paiste H, Wood KD, Assimos DG, Holmes RP, Nazzal L, Hatch M, Knight J.
    Appl Environ Microbiol; 2021 Aug 26; 87(18):e0054421. PubMed ID: 34190610
    [Abstract] [Full Text] [Related]

  • 16. Hyperoxaluria, hypocitraturia, hypomagnesiuria, and lack of intestinal colonization by Oxalobacter formigenes in a cervical spinal cord injury patient with suprapubic cystostomy, short bowel, and nephrolithiasis.
    Vaidyanathan S, von Unruh GE, Watson ID, Laube N, Willets S, Soni BL.
    ScientificWorldJournal; 2006 Apr 06; 6():2403-10. PubMed ID: 17619709
    [Abstract] [Full Text] [Related]

  • 17. Association of intestinal oxalate-degrading bacteria with recurrent calcium kidney stone formation and hyperoxaluria: a case-control study.
    Tavasoli S, Alebouyeh M, Naji M, Shakiba Majd G, Shabani Nashtaei M, Broumandnia N, Basiri A.
    BJU Int; 2020 Jan 06; 125(1):133-143. PubMed ID: 31145528
    [Abstract] [Full Text] [Related]

  • 18. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter.
    Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW.
    Am J Physiol Gastrointest Liver Physiol; 2011 Mar 06; 300(3):G461-9. PubMed ID: 21163900
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.